Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sushmita Mukherjee Chanda"'
Autor:
Sushmita Mukherjee Chanda, Christian Schwabe, E.J. Gane, Megha Patel, Oliver Lenz, Jan Snoeys, Jeysen Yogaratnam, Christopher Westland, Jennifer Vuong, Willem Talloen, Thomas N. Kakuda, Pieter Van Remoortere, John Fry
Publikováno v:
Antiviral therapy. 26(1-2)
Background Pharmacokinetics and safety of JNJ-64530440, a hepatitis B virus capsid assembly modulator producing normal empty capsids (CAM-N), in healthy volunteers were evaluated. Methods This Phase I study (NCT03439488) was a double-blind, randomise
Autor:
Leonid Beigelman, Jerome Deval, Lawrence M. Blatt, Dorothée Bardiot, Laura Vangeel, Sandro Boland, Johan Neyts, Cheng Liu, Steven Dejonghe, Dinah Misner, Andreas Jekle, Pierre Raboisson, Sushmita Mukherjee Chanda, Vladimir Serebryany, Caroline S. Foo, Koen Vandyck, Arnaud Marchand, Suping Ren, Julian A. Symons, Patrick Chaltin, Kusum Gupta, Antitsa Dimitrova Stoycheva, Dirk Jochmans, Rana Abdelnabi
Publikováno v:
Biochemical and Biophysical Research Communications
There is an urgent need for antivirals targeting the SARS-CoV-2 virus to fight the current COVID-19 pandemic. The SARS-CoV-2 main protease (3CLpro) represents a promising target for antiviral therapy. The lack of selectivity for some of the reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f364b0af0bca75044f48bf96844cbe8
https://lirias.kuleuven.be/handle/123456789/673810
https://lirias.kuleuven.be/handle/123456789/673810
Autor:
Matthew W. McClure, Christian Schwabe, Thomas N. Kakuda, Lawrence M. Blatt, John Fry, Edward Gane, Catherine A.M. Stedman, Leen Vijgen, Sushmita Mukherjee Chanda
Publikováno v:
Hepatology. 68:2145-2157
This open-label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct-acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6-12-week oral regimens of 400-800 mg once daily
Autor:
Andreas Jekle, Julian A. Symons, Sushmita Mukherjee Chanda, Vladimir Serebryany, Leonid Beigelman, Cheng Liu, Rana Abdelnabi, Suping Ren, Steven Dejonghe, Sandro Boland, Johan Neyts, Dorothée Bardiot, Dinah Misner, Antitsa Dimitrova Stoycheva, Patrick Chaltin, Jerome Deval, Pierre Raboisson, Kusum Gupta, Koen Vandyck, Dirk Jochmans, Caroline S. Foo, Arnaud Marchand, Lawrence M. Blatt, Laura Vangeel
There is an urgent need for antivirals targeting the SARS-CoV-2 virus to fight the current COVID-19 pandemic. The SARS-CoV-2 main protease (3CLpro) represents a promising target for antiviral therapy. The lack of selectivity for some of the reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b7502a8f400fdb028d390f18fc0e96d
https://doi.org/10.1101/2021.02.14.431129
https://doi.org/10.1101/2021.02.14.431129
Autor:
Jeysen Yogaratnam, John Fry, Toni Mitchell, Pieter Van Remoortere, Jennifer Rito, Thomas N. Kakuda, Malcolm Boyce, Kusum Gupta, Julian A. Symons, Sushmita Mukherjee Chanda
Publikováno v:
Antiviral Therapy. 23:555-566
Background This double-blind, first-in-human Phase I study evaluated pharmacokinetics, safety and tolerability of AL-794 (prodrug of ALS-033719), a potent endonucle-ase inhibitor of influenza A and B in healthy volunteers. Methods Healthy adult volun
Autor:
Tse-I Lin, Lawrence M. Blatt, Andreas Jekle, Dinah Misner, Pierre Jean-Marie Bernard Raboisson, Caroline G. Williams, Koen Vandyck, Sarah K. Stevens, Xuan G. Luong, Kusum Gupta, Leonid Beigelman, Julian A. Symons, Sucheta Mukherjee, Sushmita Mukherjee Chanda, David McGowan, Antitsa Dimitrova Stoycheva, Jerome Deval
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 12, p e0240338 (2020)
PLoS ONE, Vol 15, Iss 12, p e0240338 (2020)
Thyroid hormones are important modulators of metabolic activity in mammals and alter cholesterol and fatty acid levels through activation of the nuclear thyroid hormone receptor (THR). Currently, there are several THRβ agonists in clinical trials fo
Autor:
Andreas Jekle, Sushmita Mukherjee Chanda, Zhinan Jin, Yujian Hu, Jinqiao Wan, Natalia B. Dyatkina, Xiangyang Wu, Marija Prhavc, Leonid Beigelman, Vivek K. Rajwanshi, Julian A. Symons, Guangyi Wang, David B. Smith, Qingling Zhang, April Kinkade, Jerome Deval, Lawrence M. Blatt, Yuen Tam
Publikováno v:
Journal of Medicinal Chemistry. 59:4611-4624
Influenza viruses are responsible for seasonal epidemics and occasional pandemics which cause significant morbidity and mortality. Despite available vaccines, only partial protection is achieved. Currently, there are two classes of widely approved an
Autor:
Gwendoline Poizat, Marie-Claude Homery, David B. Smith, John Fry, Laure Viguerie, Christopher Westland, Alain Patat, Caroline Denot, Qingling Zhang, Jennifer Vuong, Matthew W. McClure, Sushmita Mukherjee Chanda, James Hui, David Apelian, Thomas N. Kakuda
Publikováno v:
Pharmacology Research & Perspectives
This Phase I, open‐label, two‐group, fixed‐sequence study evaluated the pharmacokinetics and safety of AL‐335, odalasvir, and simeprevir in healthy subjects. Group 1 (n = 16) received AL‐335 800 mg once daily (QD) (days 1‐3, 11‐13, and
Autor:
Jeysen Yogaratnam, C Andreas Jekle, Thomas N. Kakuda, Julian A. Symons, Pieter Van Remoortere, Sushmita Mukherjee Chanda, Toni Mitchell, Kusum Gupta, Ganesh Balaratnam, Jennifer Rito, Malcolm Boyce, John Fry, Omair Sahgal, Hein Fennema
Publikováno v:
The Journal of infectious diseases. 219(2)
Background AL-794 is an orally active prodrug of ALS-033719, which selectively inhibits the endonuclease domain of influenza virus A and B polymerase. Methods In a phase 1, double-blinded, randomized, placebo-controlled study, healthy subjects were i
Autor:
Elina Berliba, Alain Patat, Jennifer Vuong, Béatrice Astruc, Matthew W. McClure, John Fry, Leen Vijgen, Thomas N. Kakuda, Lawrence M. Blatt, Tengiz Tsertsvadze, Nick Khorlin, Adrian Streinu-Cercel, Sushmita Mukherjee Chanda, Christopher Westland, Qingling Zhang, Leonid Beigelman
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204974 (2018)
PLoS ONE
PLoS ONE
Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection. Methods This three-part randomized, double-blind study evaluated the safe